This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignees: Aelis Farma, Universitë De Bordeaux, National Institute of Health and Medical Research. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 3 
3 out of 226 
2 out of 1,853 
Years Active: 2022-2026
Title: The Innovative Journey of Inventor Stéphanie Monlezun
Introduction
Stéphanie Monlezun is a notable inventor based in Bordeaux, France. With his significant contributions to the realm of pharmaceuticals, he has made a remarkable impact on the treatment of cannabinoids-related disorders through his innovative work.
Latest Patents
Stéphanie holds a patent for a compound known as 3β-(4-methoxybenzyloxy)pregn-5-en-20-one. This invention is specifically designed for use in the treatment of cannabinoids-related disorders, showcasing a unique and promising approach in the field of medicinal chemistry.
Career Highlights
Throughout his career, Stéphanie has gained valuable experience working with prominent companies such as Aelis Pharma and the Institut National de la Santé Et de La Recherche Médicale. His contributions to these institutions reflect his commitment to advancing medical research and innovation.
Collaborations
Stéphanie has had the opportunity to collaborate with talented professionals, including Pier Vincenzo Piazza and Sandy Fabre. Together, they have worked on various projects that emphasize the importance of teamwork in driving scientific advancements.
Conclusion
In summary, Stéphanie Monlezun stands out as an accomplished inventor whose work has the potential to transform treatments for cannabinoids-related disorders. His dedication to innovation and collaboration continues to inspire the field of medical research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile